|

Hypertension Treatment in Nigeria: Hypertension Diabetes Integration Study- Formative Aim 3

RECRUITINGN/ASponsored by Washington University School of Medicine
Actively Recruiting
PhaseN/A
SponsorWashington University School of Medicine
Started2026-02-14
Est. completion2029-04-30
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

The purpose of the second phase of the Hypertension Treatment in Nigeria (HTN 2.0) Program is to build upon the success of the first phase of the HTN Program (2020-2023), which implemented the WHO HEARTS package across 60 primary healthcare centers (PHCs) in the Federal Capital Territory (FCT). This program demonstrated significant improvements in hypertension treatment and control. The focus of aim 3 will be evaluating diabetes management through the implementation of the HEARTS-D bundle in 10 PHCs across the FCT that previously participated in the initial HTN Program.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Aim 3 Inclusion Criteria:

Patients will be screened for diabetes with symptoms of hyperglycemia or BMI \>25 kg/m2 and over the age of 18 years old. Upon first or previous diagnosis, diabetes patients will be registered.

* Adults (≥18 years),
* Patients with previous diabetes diagnosis
* Patients with persistently elevated random glucose \>200 mg/dl, fasting glucose \>126 mg/dl, or hemoglobin A1c \>6.5% on two or more occasions (when available)
* Patients taking glucose lowering medications
* Pregnant women are eligible for this program, or
* Cognitively impaired adults are eligible for this program.

Exclusion Criteria:

* \- This program will not include any of the following special populations:

  * Individuals who are not yet adults (minors): i.e. infants, children, or teenagers \<18 years old, or
  * Prisoners or other detained individuals.

Conditions3

Diabete MellitusDiabetesHeart Disease

Interventions2

Related trials

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.